MRM-3379 enters patient testing for Fragile X syndrome in Mirum’s BLOOM Phase 2 trial
MRM-3379 enters Phase 2 testing for Fragile X syndrome. Find out what this means for PDE4D inhibition, IDD drug design, and future trial direction.
Pharma & Biotech
Pharma & Biotech
Can Amneal’s Parkinson’s strategy evolve beyond symptoms? KeifeRx tie-up may signal shift
KeifeRx and Amneal join forces on KFRX06, a brain-penetrant LRRK2 inhibitor for Parkinson’s. Find out what this could mean for CNS innovation.
Pharma & Biotech
Amazon adds oral Wegovy to pharmacy platform: Will this reshape obesity care logistics?
Amazon Pharmacy now delivers oral Wegovy with insurance and cash-pay options. Find out how this reshapes GLP-1 access and obesity care.
Pharma & Biotech
How Madrigal Pharmaceuticals is building a multi-mechanism MASH pipeline with the Phase 2 DGAT-2 inhibitor ervogastat
Find out how Madrigal Pharmaceuticals is building a multi-mechanism MASH pipeline with ervogastat, a Phase 2 oral DGAT-2 inhibitor.
Pharma & Biotech
How LEON’s FR-JET modular mixer achieved stable high-concentration mRNA-LNPs in a peer-reviewed study
Find out how a peer-reviewed study shows LEON’s FR-JET modular mixer enabling stable high-concentration mRNA-LNPs with enhanced in vivo activity.
Pharma & Biotech
Innovent–Ollin’s bispecific antibody OLN324 delivers superior retinal drying in DME
Ollin Biosciences and Innovent Biologics have reported positive topline results from the randomized Phase 1b JADE trial, in which OLN324 (IBI324), a next-generation VEGF/Ang2 bispecific antibody, demonstrated superior anatomical efficacy over faricimab in patients with diabetic macular edema and wet age-related macular degeneration. Conducted in over 160 patients across the United States, the head-to-head study
Pharma & Biotech
Why Biofrontera Inc.’s dual database locks mark a critical step toward validated clinical and regulatory data
Biofrontera Inc. has confirmed that databases for two of its clinical studies have been formally locked, a procedural milestone that signals the completion of data collection and validation and the transition into final statistical analysis. Although database locks rarely attract the same level of attention as topline efficacy readouts, they represent one of the most
Pharma & Biotech
Ventyx to give Lilly an oral inflammation pipeline—what’s the real upside?
Eli Lilly and Company has announced plans to acquire Ventyx Biosciences Inc. in an all-cash transaction valued at approximately $1.2 billion, securing a portfolio of clinical-stage oral small molecule therapeutics focused on chronic inflammatory-mediated diseases. The deal includes NLRP3 inhibitors such as VTX2735 and VTX3232, alongside two Phase 2 programs for inflammatory bowel disease. The
Pharma & Biotech
Sepsis breakthrough? What the EMBRACE trial reveals about Sobi’s emapalumab strategy
Swedish Orphan Biovitrum AB (Sobi) has reported positive topline data from the Phase 2a EMBRACE trial of Gamifant (emapalumab) in interferon-gamma-driven sepsis (IDS), demonstrating organ function improvement and a potential survival benefit. Based on the signal, the drug will advance in development in collaboration with the Hellenic Institute for the Study of Sepsis (HISS). The
Pharma & Biotech
Illumina expands AI-powered multiomic strategy with launch of Connected Multiomics software platform
Illumina, Inc. has officially launched Connected Multiomics, a cloud-native software platform designed to unify and analyze complex biological data across multiple omic modalities including genomics, transcriptomics, proteomics, and spatial biology. The tool is now widely available after a year-long early access program involving over 40 research groups. Positioned as a user-friendly yet technically powerful analysis